Sigma-Aldrich Partners with NHLBI, BU to Find Cardiovascular Biomarkers | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sigma-Aldrich today announced a partnership to develop methods to measure potential biomarkers for atherosclerosis cardiovascular disease in plasma samples from the Framingham Heart Study.

The partnership brings together Sigma-Aldrich, Boston University, and the National Institutes of Health's National Heart, Lung, and Blood Institute.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Sure Genomics begins to offer direct-to-consumer genome sequencing for $2,500.

Intelligence officials in the US have added gene editing to a list of weapons of mass destruction.

In Cell this week: characterization of functional genomic features in breast cancer cell lines, epigenetic pattern linked to obesity, and more.

President Obama's proposed budget for fiscal year 2017 includes an increase for NIH, but seeks some of it as mandatory funding.